Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Chronic inflammatory demyelinating polyneuropathy
Humanistic burden and health-related quality of life
7 evidence topics · 7 sources
Pain, fatigue, depression, and EQ-5D and SF-36 scores: systematic review of 7 humanistic burden studies
“Humanistic burden studies reported on the patient impact of CIDP on health-related quality of life (HRQoL), functioning, psychosocial welfare, productivity, pain, and fatigue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“2009 assessed pain and fatigue, using the Numeric Pain Rating Scale (NPRS) and Fatigue Severity Scale (FSS) scores (n = 76), reporting that 17 and 74% of patients with CIDP reported severe pain and severe fatigue, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two publications reported that 9 and 12.1% of patients had depression, based on hospital anxiety and depression scale (HADS) and the Beck Depression Inventory version II (BDI-II) scores in The Netherlands and Germany, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“EuroQol-5D (EQ-5D) scores among patients with CIDP were 0.62 and 0.68 for the UK and Germany, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A study of Dutch patients with CIDP (n = 76) also identified that patients scored below normative 36-Item Short Form Survey Instrument (SF-36) scores (50) for all the domains of the physical component and two of the domains of the mental component (vitality and social functioning)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-5L utility, fatigue, and disability in 1056 patients from eight countries, including the United States
“Data were drawn from the Adelphi CIDP Disease Specific Programme, a cross‐sectional survey with retrospective data collection, conducted in China, France, Germany, Italy, Japan, Spain, the United Kingdom, and the United States between September 2022 and April 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 164 physicians provided data for 1056 patients, with 428 (40.5%) providing self‐reported data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, mean (SD) patient‐reported scores were 62.1 (20.4) for I‐RODS, 35.0 (11.1) for FACIT fatigue, and 0.662 (0.253) for EQ‐5D‐5L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on mean EQ‐5D‐3L norms in the UK (0.856) and mean EQ‐5D‐5L norms in Germany (0.88), patients experience lower HRQoL in comparison to the general population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the use of guideline treatments, there were unmet needs and a continued disease burden for patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-3L utility and work productivity in 146 patients stable on immunoglobulin in the United States, the United Kingdom, and Germany
“Overall, 146 patients, 52 caregivers, and 81 physicians completed the survey; mean (standard deviation) patient age was 58.1 (12.8) years; time since CIDP diagnosis was 8.8 (9.3) years; 98.6% had received IVIG, and 30.8% had received SCIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (SD) EQ-5D-3L utility index and EQ-5D VAS scores in the patient cohort were 0.68 (0.23) and 62.3 (19.4), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported that CIDP prevented them (quite a bit or very much) from performing activities (50.7%), affected their social activities with family and friends (39.7%), and imposed financial burden (37.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who were currently employed, mean (SD) WPAI total productivity impairment pertaining to CIDP was 37.9% (26.6)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-state utility values by adjusted INCAT impairment level from EQ-5D data collected in ADHERE
“0.851 for very limited impairment” (opens the source at this quote in a new tab)
“0.630 for mild impairment” (opens the source at this quote in a new tab)
“0.426 for moderate impairment” (opens the source at this quote in a new tab)
“0.084 for severe impairment” (opens the source at this quote in a new tab)
“-0.216 for very severe impairment.” (opens the source at this quote in a new tab)
SF-36 improvement with immune globulin IV 10% versus placebo in 117 trial participants
“One hundred seventeen patients in a randomized, double-blind, response-conditional crossover trial received immune globulin IV, 10% caprylate/chromatography purified (IGIV-C [Gamunex(R)]), or placebo every 3 weeks for up to 24 weeks in the first period (FP).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the FP, greater improvements in both SF-36 physical and mental component scores were observed with IGIV-C vs placebo, with a significant improvement in the physical component score (difference 4.4 points; 95% confidence interval [CI] 0.7-8.0).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the EP, mean SF-36 improvements were generally improved or maintained in participants who continued IGIV-C therapy; however, worsening was observed in participants re-randomized to placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life measures in chronic inflammatory neuropathies: systematic review
“There is some evidence suggesting that baseline pre-treatment HRQoL reports are lower in patients with chronic inflammatory neuropathy than in age and gender-matched controls.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Following treatment interventions, improvements in self-reported measures were consistently documented in the physical domain of HRQoL, which in turn correlated with improvements in traditional strength and functional scales.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The impact of available treatments on the quality of life of patients with inflammatory neuropathies remains largely under-investigated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Changes in work and home life in a global survey of 595 respondents with self-reported CIDP
“Data from an online survey of 595 individuals with self-reported CIDP, recruited by the Guillain–Barré syndrome (GBS)/CIDP Foundation, were used to assess disease and treatment burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In "likely" CIDP patients 44% stopped working because of their symptoms and 24% moved to a new home.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“IVIg was associated with venous access issues and work/school absenteeism.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CIDP diagnostic confirmation was not performed in any of the survey respondents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote